Big Molecule Watch
April 28, 2017

Pfizer Files for IPR of Two Biogen Patents Directed to Rituximab

In the past few days, Pfizer has filed petitions for IPR of two of Biogen’s patents related to rituximab:  IPR2017-01166 on U.S. Patent 8,329,172 and IPR2017-01167 on U.S. Patent 8,577,244.  According to the petitions, the patents are directed to methods of treating non-Hodgkin’s Lymphoma with rituximab.

The petitions are posted on our IPR Tracker page, along with other selected documents from IPRs of biologic patents.